THE APEX TIMES
Jim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worries
A recent Yahoo Finance report highlighted CNBC host Jim Cramer’s recurring bullish view of Johnson & Johnson, pointing to what he framed as a stronger balance sheet than the government’s.
Johnson & Johnson’s stock has again surfaced in a high-profile endorsement from CNBC host Jim Cramer, according to a Yahoo Finance report published Aug. 28, 2026. The piece said Cramer has repeatedly praised the health care company during the year and that one of his central reasons is the balance sheet strength he attributes to Johnson & Johnson.
The report’s focus was not on a specific product launch, earnings beat, or contract award. Instead, it framed Johnson & Johnson as a business with financial staying power, pointing to balance-sheet resilience as a counterweight to broader market uncertainty.
Cramer’s comment, as described by Yahoo Finance, leaned on a comparison in which he characterized Johnson & Johnson’s balance sheet as “better” than what he implied about the government. The report did not provide additional context around what government measure Cramer had in mind, nor did it lay out any figures or accounting detail in the excerpt available for review.
The endorsement fits a pattern in which large, diversified health care companies are often treated by Wall Street and broadcast commentators as steadier holdings than smaller, more single-asset firms. Johnson & Johnson’s scale and long operating history can matter in discussions of credit risk, cash generation, and the ability to fund development pipelines through market cycles.
Still, the Yahoo Finance post did not disclose any new company-specific metrics in the material available for editorial review. It also did not specify whether Cramer’s remarks were tied to a particular filing, credit rating update, or a recent investor presentation, which limits how far readers can go in validating the balance-sheet claim.
For investors and analysts, the immediate takeaway is that the conversation around Johnson & Johnson in this instance was driven by financial durability rather than a discrete catalyst. What happens next, notably in the company’s next quarterly reporting cycle or any debt and liquidity disclosures, will determine whether that durability view is reinforced by updated numbers.
Why It Matters
- High-profile commentary can influence short-term sentiment, particularly for large-cap health care names that investors often view as lower-volatility relative to smaller companies.
- Balance-sheet strength is a key input to how investors think about liquidity risk and a company’s ability to continue funding operations and pipeline activities through downturns.
- Because the comparison to “the government” was not quantified in the available text, readers may need to look to Johnson & Johnson’s next filings to understand what financial measures are being implied.
- If the market interprets Cramer’s remarks as indicating resilience without a near-term catalyst, it could support sustained interest in the stock even when newsflow is light.
Key Facts
- Yahoo Finance reported on Aug. 28, 2026 that Jim Cramer has repeatedly praised Johnson & Johnson during the year.
- The report characterizes Cramer’s view of Johnson & Johnson as tied to balance-sheet strength.
- The Yahoo Finance piece includes a comparison in which Cramer framed Johnson & Johnson’s balance sheet as stronger than what he implied about the government.
- The available report excerpt did not include specific Johnson & Johnson balance-sheet figures or the specific government reference behind the comparison.
- The company’s ticker is Johnson & Johnson (NYSE:JNJ), as referenced by the Yahoo Finance headline.
Healthcare Related
AM Best affirms UnitedHealth’s credit ratings at “a-,” maintaining long- and short-term issue ratings
The rating agency said it reaffirmed UnitedHealth Group’s long-term issuer credit rating and related long- and short-term issue credit ratings for the company and its subsidiaries.
Moderna Q2 earnings spotlighted as analysts place its results in the wider therapeutics-stock landscape
A Yahoo Finance wrap-up of second-quarter results put Moderna’s performance in context with other healthcare therapeutics stocks, underscoring how investors weigh growth, pipeline progress, and near-term fundamentals.
FDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patients
The agency has cleared Mounjaro for a new indication aimed at lowering the risk of major cardiovascular events among adults with Type 2 diabetes who are considered at higher risk for heart attack or stroke.
Novo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains central
A regulatory step in China for Novo’s obesity medicine supports the possibility of a future launch, yet it does not resolve timing risks or guarantee approval. Eli Lilly still has a prominent position as the battle over GLP-1 oral therapy extends.
Pfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patients
The company’s newly updated shot, adapted from its XFG program, is being rolled out with deliveries starting immediately to pharmacies and clinics.
Lilly’s Mounjaro franchise grows after FDA expands label into heart-risk population
Eli Lilly (LLY) says the FDA decision broadens Mounjaro’s U.S. use beyond glucose control, adding a heart-risk label that strengthens its competitive position in cardiometabolic care.
David Tepper exits UnitedHealth as focus returns to fair value accounting
The hedge-fund manager’s sale of his UnitedHealth Group position is prompting investors to re-check how the company measures and reports fair value assets and liabilities, even as the broader healthcare giant continues to operate on steady core fundamentals.
Eli Lilly shares have held up better than the Dow over the past year, according to market-watchers
A recent market recap highlights Eli Lilly’s stock outperformance versus the Dow over 12 months and points to continuing Wall Street optimism about the company’s longer-term growth prospects.
Eli Lilly credited with “major FDA win” for weight-loss drug in latest market report
A Yahoo Finance report on Aug. 28 said the company’s weight-loss pipeline received a significant boost from the U.S. Food and Drug Administration, strengthening one of its most important growth areas.
Moderna and Merck report late-stage win for personalized melanoma vaccine with Keytruda
The companies said their Phase 3 trial of intismeran plus Merck’s Keytruda met its stated goals in a study of 1,137 patients.